Evidence map›Paper›PMID 40886013›Full record

ArticleAIDS research and therapy2025

Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana.

Nicholas Ekow Thomford, Tracy Kellermann, Joel Adu Twum, John Anyimadu, Charné Dixon, Dennis Sappor, Dee Blackhurst, Prince Amoah Barnie, Oksana Ryabinina, Samuel Badu Nyarko and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nicholas Ekow ThomfordPharmacogenomics and Genomic Medicine Group, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana. nthomford@ucc.edu.gh.
Tracy KellermannDivision of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Joel Adu TwumPharmacogenomics and Genomic Medicine Group, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
John AnyimaduPharmacogenomics and Genomic Medicine Group, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Charné DixonDivision of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Dennis SapporPharmacogenomics and Genomic Medicine Group, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Dee BlackhurstDepartment of Pathology, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town, 7925, South Africa.
Prince Amoah BarnieDepartment of Forensic Sciences, School of Biological Sciences, College of Natural Sciences, University of Cape Coast, Cape Coast, Ghana.
Oksana RyabininaDepartment of Chemical Pathology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Samuel Badu NyarkoPharmacogenomics and Genomic Medicine Group, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Robert Peter BineyDepartment of Pharmacotherpaeutics and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of Cape Coast, Cape Coast, Ghana.
Martins EkorDepartment of Pharmacology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
George B KyeiMedical and Scientific Research Centre, University of Ghana Medical Centre, Legon, Accra, Ghana.

Funding

European and Developing Countries Clinical Trials Partnership TMA2019CDF-2670
6 · The paper itself

Abstract

backgroundHuman Immunodeficiency Virus and malaria are significant public health challenges in sub-Saharan Africa, contributing substantially to morbidity and mortality in the region. The trajectory of HIV and malaria mono- and coinfections may be different with presentations of drug-drug and disease-disease interactions. Current medications of artemether-lumefantrine and dolutegravir (DTG) -based anti-retroviral therapy which are the preferred drugs are metabolised by CYP2B6, CYP3A4/5 and UGTs which are polymorphic and may contribute to drug disposition and clinical outcomes. This study investigated the pharmacogenetic effects of co-administration of arthemeter-lumfantrine and DTG in HIV-malaria mono and coinfection.

methodsMalaria and HIV mono- and coinfected participants were recruited from health facilities in the Central region of Ghana. Blood samples were taken at pre-defined time points during malaria and HIV mono- and coinfection. Plasma drug concentrations of artemether-lumefantrine and dolutegravir and their metabolites of dihydroartemisinin and desbutyl-lumefantrine were determined by liquid chromatography-mass spectrometry (LC-MS/ MS). Genotyping for CYP2B6, UGT1A, CYP3A4 and CYP3A5 was undertaken using PCR-RFLP, TaqMan assays and Iplex GOLD SNP genotyping protocol.

resultsTwo hundred and sixty-one participants were involved in this study, with a male to female ratio of 1:2. Median parasitaemia for malaria monoinfection and HIV-malaria coinfection was 947.34 parasites/µL of whole blood and 5287.36 parasites/µL of whole blood respectively on day 1. By days 3 and 7, the parasitaemia had decreased to 0 for both malaria monoinfection and HIV-malaria coinfections. Plasma median C

conclusionsThere is an observed decrease in plasma drug concentrations during the co-administration of artemether-lumefantrine and dolutegravir. Possible long-term effects from non-adherence may include sub-optimal levels that could result in clinical differences and outcomes.

Indexed as

AntimalarialsArtemether, Lumefantrine Drug CombinationHIV InfectionsHIV Integrase InhibitorsMalariaAdultCoinfectionDolutegravirDrug InteractionsFemaleGhanaHeterocyclic Compounds, 3-RingHumansMaleMiddle AgedOxazinesAntimalarialsArtemether, Lumefantrine Drug CombinationDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesArtemether lumefantrineCYP3A4CYP3A5DolutegravirDTGHIVPharmacogenomicsPlasma drug concentrationUGT1A1Viral load

Identifiers

PMID40886013
PMCPMC12398046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.